Stay updated on CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Sign up to get notified when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.

Latest updates to the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page
- Check3 days agoChange DetectedNo significant content changes detected between the old and new page; core study details, eligibility criteria, outcomes, and locations appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check10 days agoNo Change Detected
- Check32 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference5%

- Check39 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page now displays Revision: v3.0.2, replacing the previous v3.0.1; the Back to Top element has been removed as a minor UI change.SummaryDifference0.3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, pricing, or availability.SummaryDifference0.3%

- Check68 days agoChange DetectedThe web page has been updated to include a new facility name, location details, and a list of publications related to a specific clinical study, while removing outdated location terms and references to certain diseases.SummaryDifference16%

Stay in the know with updates to CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX130 in Relapsed/Refractory T/B Malignancies Clinical Trial page.